Abstract
Objective To study the safety of apatinib combined with chemotherapy in the treatment of advanced gastric carcinoma (GCA). Methods 74 patients with advanced GCA treated in the oncology department of Weifang People's Hospital (January 2019–January 2020) were enrolled in this study and equally split into study group (SG) and reference group (RG) according to the odd and even admission numbers. RG underwent chemotherapy alone, while SG received apatinib combined with chemotherapy. The clinical indicators of serum matrix metalloproteinase 9 (MMP-9), serum interleukin-2 receptor (SIL-2R), and immune cell level were detected in the two groups before and after treatment to analyze the therapeutic effect of different treatment methods on patients with advanced gastric carcinoma. Results No obvious differences in gender ratio, average age, average BMI, pathological staging, pathological types, organ metastasis types, and residence were observed between the two groups (P > 0.05). The short-term follow-up results showed that the disease control rate (DCR) in SG was markedly higher compared with RG (P < 0.05). The MMP-9 and SIL-2R levels in both groups after treatment decreased (P < 0.05), and the levels in SG after treatment were notably lower compared with RG (P < 0.001). Compared with RG, CD3+, CD4+, and CD4+/CD8+ levels in SG after treatment were notably higher (P < 0.001), while the CD8+ level was notably lower (P < 0.001). The median progression-free survival (MPFS) and overall survival (OS) in SG were markedly higher compared with RG (P < 0.001). The GQOLI-74 scores in both groups after treatment increased (P < 0.001), and the GQOLI-74 score in SG after treatment was markedly higher compared with RG (P < 0.001). The total incidence of adverse reactions was lower in SG than in RG (P < 0.05). Conclusion Apatinib combined with chemotherapy is superior to chemotherapy alone in effectively improving treatment outcomes in patients with advanced GCA.
Highlights
Gastric carcinoma (GCA) is a common tumor disease in gastroenterology
Chemotherapy is the main way to prolong the survival time of patients with advanced GCA, but there is no standard scheme for chemotherapy at present. e common chemotherapy drugs include antimicrotubule, fluorouracil, and platinum drugs, which can reduce the gastrointestinal reaction of patients to a certain extent and delay the disease progression [13, 14]
Vascular endothelial growth factor (VEGF) plays an important role in the process of abnormal angiogenesis, which is mainly secreted by tumor cells or tumor stromal cells
Summary
Gastric carcinoma (GCA) is a common tumor disease in gastroenterology. China is a country with a high incidence of GCA, and about 350,000 people die from GCA every year.erefore, GCA has become the main cancer that endangers human life and health [1,2,3]. Gastric carcinoma (GCA) is a common tumor disease in gastroenterology. China is a country with a high incidence of GCA, and about 350,000 people die from GCA every year. Erefore, GCA has become the main cancer that endangers human life and health [1,2,3]. Due to unreasonable diet structure, high working pressure, chronic atrophic gastritis, and other reasons, GCA patients tend to be younger. Since the early clinical symptoms of GCA are not obvious, most patients have missed the best treatment opportunity. Chemotherapy is the main treatment for prolonging the survival period of patients at present, and there is no standard scheme for chemotherapy. Oxaliplatin is widely applied to slow down the disease progression and relieve the clinical symptoms, with good short-term curative
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
